The Magnesium Sulphate prices witnessed a monthly increase of x.xx in the European region during August xxxx. The producers raised their Magnesium Sulphate quotations amid consistent demand and inadequate availability of supplies in the market. The market sentiments for Magnesium Sulphate were bullish as the demand was robust from the regional pharma sector. SCHOTT Pharma saw a revenue boost of xxx in the second quarter of xxxx, reaching EUR xxx million at constant currencies, up from EUR xxx million in Qx xxxx. Although revenue rose, EBITDA saw a modest dip due to ramp-up expenses from ongoing capacity expansions and a high comparative base, resulting in an EBITDA margin of xx.xx, down from xx.xx the previous year. Additionally, reported revenues and EBITDA were impacted by notable currency headwinds. Despite these challenges, demand for SCHOTT Pharma’s products remained strong, highlighting favorable market conditions, and reinforcing the company’s growth...
